Lactiplantibacillus plantarum AL4510, isolated from traditional fermented goat milk on the Qinghai-Tibet Plateau, reduced liver and colon cellular senescence markers (SA-β-gal, p16) by approximately 50–60% in two simultaneously run mouse aging models: D-galactose-induced metabolic aging and hypobaric hypoxia-induced aging. The strain restored antioxidant enzymes SOD and GSH-Px, lowered MDA, suppressed IL-1β and TNF-α, and rebalanced the gut microbiome by suppressing a pathogenic trio (Desulfovibrio, Bilophila, Helicobacter) while elevating Akkermansia, Muribaculum, and Lactobacillus. Metabolomically, AL4510 replenished acetate, propionate, and butyrate in both models, while deploying etiology-specific metabolites — spermidine and lipoxin B4 for D-gal, catalpol and calcium pantothenate for hypoxia.
The concept of a probiotic with both convergent and divergent mechanistic tracks is genuinely novel. Most anti-aging probiotic research tests a single insult model, making the side-by-side dual-model design here a meaningful methodological advance. The 50–60% senescence reduction is a striking effect size, though all data come from rodents, and translation to humans remains speculative. The identification of spermidine elevation is particularly compelling — autophagy-inducing polyamines have strong independent longevity evidence in model organisms and emerging human data. High-altitude-adapted strains may carry stress-resilience traits (oxidative tolerance, cold adaptation) that standard commercial probiotics lack, making the Tibetan microbiome a potentially underexplored reservoir. This is a solid mechanistic proof-of-concept study, but human clinical validation and dose-optimization trials are essential before any practical longevity application can be claimed.
